Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
STADA Arzneimittel Aktiengesellschaft, commonly referred to as STADA, is a prominent player in the pharmaceutical preparation manufacturing industry, headquartered in Germany. Founded in 1895, the company has established a strong presence across Europe and beyond, focusing on the development and production of high-quality generic and over-the-counter (OTC) products.
STADA's core offerings include a diverse range of pharmaceuticals, particularly in the areas of pain relief, allergy treatment, and dermatology. What sets STADA apart is its commitment to quality and accessibility, ensuring that essential medications are available to a broad audience. With a robust market position, STADA has achieved significant milestones, including strategic acquisitions that have expanded its product portfolio and global reach. As a trusted name in the pharmaceutical sector, STADA continues to innovate and adapt to meet the evolving needs of healthcare providers and patients alike.
+16 vs industry average
STADA Arzneimittel Aktiengesellschaft’s score of 58 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
STADA Arzneimittel Aktiengesellschaft, headquartered in Germany and operating in Pharmaceutical Preparation Manufacturing, reported approximately 739.8 million kg CO2e in total carbon emissions for 2025. This includes about 42.8 million kg CO2e from Scope 1 emissions, approximately 26.1 million kg CO2e (market-based) from Scope 2 emissions, and about 670.9 million kg CO2e from Scope 3 emissions. Key contributors to Scope 3 emissions in 2025 were purchased goods and services (approximately 566.5 million kg CO2e) and upstream transportation and distribution (approximately 38.5 million kg CO2e).
For 2023, STADA's total emissions were approximately 754.6 million kg CO2e, comprising about 40.1 million kg CO2e in Scope 1, approximately 41.7 million kg CO2e (market-based) in Scope 2, and about 672.8 million kg CO2e in Scope 3.
STADA has set a near-term target to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2020 as the base year. The company has also committed to a 1.5°C global warming target, aligning with the Paris Agreement, which includes increasing renewable energy and energy efficiency. STADA Arzneimittel Aktiengesellschaft's SBTi target status is "Committed."
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about STADA Arzneimittel Aktiengesellschaft’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more